Journal of Nanobiotechnology · 2021 · 48 citations · 36 references
PharmacyOncologyPharmacologyDrug DeliveryNanoparticle Drug DeliveryTumor MicroenvironmentCancer NanomedicineNanocarriers For TherapeuticsNanoparticle DesignTargeted Cancer TherapyTargeted TherapyTumor Microenvironment ModulationCancer-associated Fibroblast TargetingFibroblast ActivationMicellesNanocarrier-based ProdrugsNanoparticle DeliveryPolymer MicellesPolymeric MicellesTumor-targeted Prodrugs
BACKGROUND: The prognosis of patients with advanced gastric cancer (GC) remains unsatisfactory owing to distant metastasis and resistance to concurrent systemic therapy. Cancer-associated fibroblasts (CAFs), as essential participators in the tumor microenvironment (TME), play a vital role in tumor progression. Thus, CAFs-targeting therapy is appealing for remodeling TME and sensitizing GC to conventional systemic therapy. METHODS: Amphiphilic SN38 prodrug polymeric micelles (PSN38) and encapsulated the hydrophobic esterase-responsive prodrug of Triptolide (TPL), triptolide-naphthalene sulfonamide (TPL-nsa), were synthesized to form PSN38@TPL-nsa nanoparticles. Then, CAFs were isolated from fresh GC tissues and immortalized. TPL at low dose concentration was used to investigate its effect on CAFs and CAFs-induced GC cells proliferation and migration. The synergistic mechanism and antitumor efficiency of SN38 and TPL co-delivery nanoparticle were investigated both in vitro and in vivo. RESULTS: Fibroblast activation protein (FAP), a marker of CAFs, was highly expressed in GC tissues and indicated poorer prognosis. TPL significantly reduced CAFs activity and inhibited CAFs-induced proliferation, migration and chemotherapy resistance of GC cells. In addition, TPL sensitized GC cells to SN38 treatment through attenuated NF-κB activation in both CAFs and GC cells. PSN38@TPL-nsa treatment reduced the expression of collagen, FAP, and α-smooth muscle actin (α-SMA) in tumors. Potent inhibition of primary tumor growth and vigorous anti-metastasis effect were observed after systemic administration of PSN38@TPL-nsa to CAFs-rich peritoneal disseminated tumor and patient-derived xenograft (PDX) model of GC. CONCLUSION: TPL suppressed CAFs activity and CAFs-induced cell proliferation, migration and chemotherapy resistance to SN38 of GC. CAFs-targeted TPL and SN38 co-delivery nanoparticles exhibited potent efficacy of antitumor and reshaping TME, which was a promising strategy to treat advanced GC.
36
Yung‐Jue Bang, Eric Van Cutsem, A. Feyereislova et al. · The Lancet · 2010 · 7.3K citations · Full text
Medicine, Oncology, Pharmacotherapy +17
Comprehensive molecular characterization of gastric adenocarcinoma
Adam J. Bass, Vésteinn Thórsson, David Van Den Berg et al. · Nature · 2014 · 6.5K citations · Full text